^
    Back
    Association details:
    Biomarker:FOLR1 expression
    Cancer:Ovarian Cancer
    Drug:luveltamab tazevibulin (STRO-002) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

    Excerpt:
    ...Positive FOLR1 expression per central laboratory testing 5....
    Trial ID:
    REFRaME-O1
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.

    Published date:
    05/25/2023
    Excerpt:
    Endpoint...ORR (95% CI)...37.5% (21.1, 56.3)...These dose expansion data confirm activity of luvelta at starting doses ranging from 4.3-5.2 mg/kg in recurrent OC with FolRα expression as low as TPS>25% and supports further clinical study in this population.
    DOI:
    10.1200/JCO.2023.41.16_suppl.5508
    Trial ID:
    STRO-002-GM1